What pharma sponsors actually look at on a CRO’s website before sending an RFI

Key takeaways

• Pharma sponsors read a CRO’s website like a vendor qualification packet before deciding whether to send an RFI.
• Therapeutic area pages need named indications, phase experience, regulatory history and the experts behind each area.
• Compliance sections should name current standards such as ICH E6(R3), which replaced E6(R2), and describe the quality system.
• Service pages need operational detail: site networks, recruitment approach, EDC platforms and biostatistics structure.
• Missing details lead sponsors to assume the capability does not exist, so gaps cost RFIs.

Pharma sponsors review a CRO’s website for proof of therapeutic expertise, compliance discipline, team depth, operational detail and global reach before sending an RFI. They form opinions long before they contact you. This Emulent guide walks through what sponsors look for on each part of your site and what they conclude when it is missing.

Does your website signal the right therapeutic expertise?

Your website signals the right expertise when sponsors can quickly confirm you have run studies like theirs. They look for a specific track record in their indication, not a general overview, and vague phrases like “broad therapeutic expertise” raise concerns.

Sponsors read your site much as they would a qualification packet. Pages that sound like marketing copy rather than evidence lose credibility fast.

• List the exact conditions you have worked in rather than broad areas such as oncology or neuroscience alone, since sponsors search by indication.
• State whether your team has run Phase I, II, III or IV trials in each area.
• Note relevant IND filings, NDA or BLA support and FDA interactions for each area.
• Name team members with direct clinical or scientific experience in each area.

How do sponsors read your regulatory and compliance section?

Sponsors read your compliance section as evidence of how much risk you would add to their program. A one-line claim of “GCP compliance” is not enough. They want to see quality built into operations.

Name current standards. ICH E6(R3), the updated Good Clinical Practice guideline, was finalized by ICH in January 2025, and regulators have since adopted it. A site that still cites only E6(R2) looks out of date.

• Name the standards you follow, including ICH E6(R3) GCP and applicable FDA and EMA requirements.
• State that you run a documented quality management system with clear ownership, even if you do not publish SOPs.
• Describe your audit, inspection and CAPA processes in general terms, sharing outcomes only where clients permit.
• List the submission types you have supported, such as IND, NDA, BLA or MAA, and in which regions.

Sponsors are buying risk management as much as execution capacity, so a buried or missing compliance story is a red flag.

What does your leadership and team page actually communicate?

Your team page communicates whether sponsors can trust the people who will run their study. Sponsors are entering a long relationship with the team handling execution, regulatory review and day-to-day decisions, so a page of headshots and titles falls short.

• Put advanced degrees, pharma or regulatory experience and specialized training up front.
• Link bios to therapeutic areas so sponsors can find the right experts without reading every profile.
• Show tenure and career continuity, which signals your CRO will not lose program knowledge mid-trial.
• Describe the roles leaders have held, such as project director or regulatory lead, and the scope of programs they ran.

Do your service pages show operational depth or surface-level summaries?

Service pages need operational depth, because a list of “clinical trial management, data management and regulatory affairs” tells a serious sponsor nothing new. Sponsors planning global studies want to understand what is actually inside each offering.

• Describe your site network, including the number of investigator sites, regions covered and preferred site relationships.
• Explain your recruitment approach, including digital tools, registries and plans for representative enrollment, since enrollment risk worries sponsors most.
• Name the EDC and other systems you use, such as Medidata Rave or Veeva Vault, because sponsors have platform preferences.
• State whether biostatistics and data management are in-house or outsourced, and describe experience with adaptive and complex designs.

How does your website handle global reach and specialty capabilities?

Your website handles global reach well when it shows exactly where you operate and which specialty capabilities you bring. Sponsors look for proven capacity in the US, EU, Asia-Pacific and Latin America, and a site that hides international reach may be skipped.

Decentralized elements are now mainstream enough that sponsors expect detail. FDA issued final guidance on conducting clinical trials with decentralized elements in September 2024, covering telehealth visits, in-home visits and local healthcare providers.

• List countries and regions where you operate, and note local offices and in-country regulatory staff.
• Explain how you run decentralized elements, including remote consent, home visits, local provider coordination and data capture.
• Describe rare disease experience with small populations, natural history studies and orphan drug pathways.
• Note documented work in pediatric, elderly or other special populations.

What do sponsors conclude when they cannot find what they are looking for?

Sponsors conclude that missing information means missing capability. They treat your website as your best case, so if it is vague or hard to use, they assume working with you will be the same.

• If services are not mapped to indications, sponsors stop searching and move on.
• If EDC, CTMS or eCOA platforms are not named, sponsors question whether your data practices are current.
• If team pages lack credentials and program scope, your team looks interchangeable with competitors’.
• If there is no clear path to a scientific or business development contact, sponsors often contact another CRO instead.

Most CROs think of their website as a branding tool, while sponsors use it as a qualification checklist. Closing that gap turns the site into a source of RFIs.

What does this mean for your CRO’s digital presence?

For your CRO, it means the website must speak the clinical and regulatory language sponsors use, show the depth behind each service and make it easy to reach the right expert. Sponsors doing pre-RFI research are experienced evaluators who decide quickly whether you belong on their list.

Emulent works with CROs and life sciences organizations to build websites and content strategies that turn sponsor interest into RFI submissions. Contact the Emulent team to review what your site tells sponsors today.